Skip to content
All resources

Growth hormone peptides

Sermorelin vs CJC-1295: GHRH Analogues and the DAC Question

EC

By

· 2 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 6 sections
  1. A shared signalling pathway
  2. DAC changes the experiment
  3. Why half-life claims differ
  4. Evidence and regulatory context
  5. Frequently asked questions
  6. Further reading

Quick answer: Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone; modified GHRH analogues alter the sequence to change properties. The most important comparison is identifying the exact CJC-1295 species in the study.

A small peptide bound to the surface of a large globular protein
Illustration: the DAC idea, a peptide hitched to albumin.

A shared signalling pathway

Sermorelin and modified growth-hormone-releasing factor analogues act on the GHRH receptor. That receptor is not the same as the ghrelin receptor targeted by ipamorelin. Understanding receptor identity prevents misleading “same effect, different duration” claims.

DAC changes the experiment

The compound studied as CJC-1295 with DAC includes a drug-affinity-complex modification associated with prolonged exposure. Products marketed as CJC-1295 without DAC are commonly described as modified GRF(1-29). Clinical findings for a DAC-bearing molecule should not automatically be transferred to a non-DAC analogue.

Why half-life claims differ

Half-life depends on which molecule was studied, the assay, the biological matrix and whether investigators measured free or total signal. A half-life quoted without identifying the compound and the source paper is not a reliable comparison.

Evidence and regulatory context

Historical approval or discontinuation of a sermorelin medicine does not confer authorization on a contemporary research vial. Nor does demonstrating a change in hormone concentration establish improved health outcomes. The core evidence gap is the leap from endocrine biomarkers to clinically meaningful benefits.

Frequently asked questions

Is CJC-1295 the same as sermorelin? No; related GHRH signalling does not mean identical molecular composition.

Does without DAC mean the same human evidence applies? No. Verify which exact molecule a paper tested.

Supplied here for laboratory use: CJC-1295 / Ipamorelin Blend. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Further reading

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.